Navigation Links
Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors

SAN DIEGO, July 24, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the appointment of Dr. Stephen Newman to its Board of Directors.  Dr. Newman is the former Vice Chairman and Chief Operating Officer of Tenet Healthcare Corporation (THC), a health care delivery and services company, until his retirement in June 2012.


"Dr. Newman's extensive leadership and experience, ranging from medical practitioner to COO of a major health care delivery system operating several dozen hospitals and providing services to hundreds of institutions, brings tremendous insight and value to Optimer's Board, particularly in these early stages of introducing DIFICID to the health care system," said Pedro Lichtinger, President and CEO of Optimer.

Dr. Newman, 62, most recently served as Vice Chairman and Chief Operating Officer of Tenet Healthcare Corporation until his retirement in June 2012. Dr. Newman joined Tenet in February 1999 and held various positions of increasing responsibility before eventually becoming COO, including Chief Executive Officer for Tenet's California region. Before joining Tenet, Dr. Newman held executive positions at Columbia/HCA Inc. from April 1997 to February 1999 and served as Senior Vice President and Chief Medical Officer of Touro Infirmary in New Orleans from August 1990 to March 1997. Prior to 1990, Dr. Newman served as Associate Professor of Pediatrics and Medicine at Wright State University School of Medicine and as Director of Gastroenterology and Nutrition Support at Children's Medical Center in Dayton, Ohio.  Dr. Newman recently completed a five-year term on the Board of Directors of the Federation of American Hospitals and presently serves on the Federal Reserve Bank of Atlanta's Labor Education and Healthcare Advisory Committee. Dr. Newman holds a bachelor's degree from Rutgers University, an M.B.A. from Tulane University and a medical degree from the University of Tennessee. He completed his internship, residency and fellowship at Emory University School of Medicine. Dr. Newman also completed the Advanced Management Program at the University of Pennsylvania's Wharton School of Business.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved macrolide antibacterial drug for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older and is commercializing DIFICID in the US and Canada. Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™. The Company is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem.  Additional information can be found at

Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications

Canale Communications
Jason I. Spark, Senior Vice President

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
2. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
3. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
4. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
5. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
6. MAP Pharmaceuticals Reports Second Quarter of 2012 Financial Results
7. Onyx Pharmaceuticals To Report Second Quarter 2012 Financial Results After Market On August 1, 2012
8. Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation
9. Webcast Alert: Isis Pharmaceuticals Second Quarter 2012 Financial Results Conference Call
10. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at
11. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused on ... of various clinical conditions, today announced the closing of ... Depository Shares ( ADSs ), each representing 20 ordinary ... to 3,158,900 ADSs. The ADSs and warrants were issued ...
(Date:11/25/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a developer ... Officer Antonius Schuh, Ph.D., is scheduled to present a ... Jaffray Healthcare Conference. th Annual Piper ... in New York on Tuesday, ... will be available for one-on-one meetings during the conference. ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has been recognized once again for its stellar workplace culture with the company’s ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati ...
(Date:11/25/2015)... (PRWEB) , ... November 26, 2015 , ... ... Union Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and ... Office in Nairobi (UNON) for the opening of the 5th African Network for ...
(Date:11/25/2015)... , ... November 25, 2015 , ... According to an ... robot is being more and more widely heralded as a breakthrough for performing hernia ... method has over traditional laparoscopic surgery is that it can greatly reduce the pain ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... ... , ... On November 23rd 2015 Cozy Products, a division of ... Cozy Products explains what this means for business moving forward. , The Tri Lite ... business model: to sell personal heaters that reduce energy consumption, are economical and keep ...
Breaking Medicine News(10 mins):